HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes.

Abstract
Pentostatin is an adenosine deaminase (ADA) inhibitor with antineoplastic activity. CD26 is a surface glycoprotein with a key role in T cell function as the ADA binding protein. We conducted a phase II study to evaluate pentostatin efficacy in relapsed T-non-Hodgkin's lymphoma (T-NHL) and to correlate response with tumor CD26 expression. We also examined the lymphopenic effect of pentostatin on CD26+ T lymphocytes. Eighteen patients were registered for the study. Pentostatin was administered as intravenous bolus daily over 3 days at an initial dose of 5 mg/m(2)/day, repeated every 4 weeks. CD26 surface expression on tumor cells and T lymphocytes was determined by flow cytometry. Out of 14 patients evaluable for response, there was 1 (7%) complete response (CR) and 6 (43%) partial responses (PR). Median progression-free survival for responders was 6 months (range: 2-15 months); median number of courses was 4 (range: 1-6). Responders included 1 of 2 CD26+ and 5 of 9 CD26- cases. Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression. We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications.
AuthorsNam H Dang, Fredrick B Hagemeister, Madeleine Duvic, Jorge E Romaguera, Anas Younes, Dan Jones, Barry Samuels, Luis E Fayad, Barbara Pro, Felipe Samaniego, Andreas Sarris, Andre Goy, Peter McLaughlin, Ann T Tong, Pamela L Walker, Lili Paz Tiongson, Terry L Smith, Yang O Huh, Chikao Morimoto, Maria A Rodriguez
JournalOncology reports (Oncol Rep) 2003 Sep-Oct Vol. 10 Issue 5 Pg. 1513-8 ISSN: 1021-335X [Print] Greece
PMID12883733 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibiotics, Antineoplastic
  • Pentostatin
  • Dipeptidyl Peptidase 4
Topics
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (adverse effects, therapeutic use)
  • Dipeptidyl Peptidase 4 (biosynthesis)
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Lymphoma, T-Cell (drug therapy)
  • Male
  • Middle Aged
  • Pentostatin (adverse effects, therapeutic use)
  • T-Lymphocytes (metabolism)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: